Renal vascular disease in neurofibromatosis type 2: Association or coincidence?

Developmental Medicine and Child Neurology

Volumn 48, Issue 1, 2006, Pages 58-59

  Cordeiro, Nuno J V ^a   Gardner, Kate R ^a   Huson, Susan M ^b   Stewart, Helen ^b   Elston, John S ^c   Howard, Emma L ^d   Tullus, Kjell O ^e   Pike, Michael G ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c OXFORD EYE HOSPITAL   (United Kingdom)

^d ST MARY S HOSPITAL   (United Kingdom)

^e GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CASE REPORT; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; EYE DISEASE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HYPERTENSION; INFANT; MALE; NEUROFIBROMATOSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RENOVASCULAR DISEASE; SKIN MANIFESTATION;

BLOOD PRESSURE; GENES, NEUROFIBROMATOSIS 2; HUMANS; HYPERTENSION, RENOVASCULAR; INFANT; MALE; MUTATION; NEUROFIBROMATOSIS 2;

EID: 31144458999     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1017/S0012162206000119     Document Type: Article

References (13)

1. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DGR. (2002) Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59: 1759-1765.
2. De Vitis LR, Tedde A, Vitelli F, Ammannati F, Mennonna P, Bigozzi U, Montali E, Papi L. (1996) Screening for mutations in the neurofibromatosis type 2 (NF2) gene in sporadic meningiomas. Hum Genet 97: 632-637.
3. Egan RA, Thompson CR, MacCollin M, Lessell S. (2001) Monocular elevator paresis in neurofibromatosis type 2. Neurology 56: 1222-1224.
4. Evans DGR, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. (1992) A clinical study of type 2 neurofibromatosis. Quart J Med 84: 603-618.
5. Huson SM, Canham N. (2003) Neurofibromatosis. In: Flinter F, Maher E, Saggar-Malik A, editors. The Genetics of Renal Disease. Oxford: Oxford University Press. p 349-359.
6. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW. (2002) Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 97: 290-296.
7. Janse AJ, Tan WF, Majoie CBLM, Bijlsma EK. (2001) Neurofibromatosis type 2 diagnosed in the absence of vestibular schwannomas. A case report and guidelines for a screening protocol for children at risk. Eur J Pediatr 160: 439-443.
8. MacCollin M, Ramesh V, Jacoby LB, Louis DN, Rubio M, Pulaski K, Trofatter JA, Short MP, Bove C, Eldridge R, Parry DM, Gusella JF. (1994) Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet 55: 314-320.
9. McClatchey AI. (2003) Merlin and ERM proteins: Unappreciated roles in cancer development? Nature Rev Cancer. 3: 877-883.
10. Nunes F, MacCollin M. (2003) Neurofibromatosis 2 in the pediatric population. J Child Neurol 18: 718-724.
11. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. (1994) Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52: 450-461.
12. Ragge NK, Baser ME, Klein J, Nechiporuk A, Sainz J, Pulst SM, Riccardi VM. (1995) Ocular abnormalities in Neurofibromatosis 2. Am J Ophthalmol 120: 634-641.
13. Shimizu T, Seto A, Maita N, Keisuke H, Tsukita S, Hakoshima T. (2002) Structural basis for neurofibromatosis type 2. Crystal structure of the merlin FERM domain. J Biol Chem 277: 10332-10336.